Industry stockpiles of active pharmaceutical ingredients assembled in response to new import regulations have successfully staved off any continentwide API shortages for the time being, according to representatives from several European pharma and chemical groups. In addition, firms in API-exporting countries such as China have been working hard to issue required written confirmations of quality, according to Stefan Kettelhoit of Blue Inspection.

Related Summaries